Brief: Revive Therapeutics Provides Update Of Phase 3 Clinical Study For Bucillamine In The Treatment Of Covid-19
12/05/2023 13:16
May 12 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE OF PHASE 3 CLINICAL
STUDY
FOR BUCILLAMINE IN THE TREATMENT OF COVID-19
* REVIVE THERAPEUTICS LTD: DSMB RECOMMENDED THAT STUDY BE
HALTED
EARLY DUE TO STATISTICAL SIGNIFICANCE OF PRIMARY ENDPOINT LIKELY
NOT GOING TO BE MET
* REVIVE THERAPEUTICS LTD: COMPANY HAS HALTED STUDY AND WILL
NOW
PROCEED TO UNBLIND AND SEEK AN EVALUATION OF STUDY'S DATA
* REVIVE THERAPEUTICS LTD: COMMITTED TO ADVANCING CLINICAL
AND
COMMERCIAL DEVELOPMENT OF BUCILLAMINE
Source text for Eikon: ID:nGNX1lrpMt
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure